Song Ping, Jin Yuqi, Fu Linglin, Yang Fengming, Tan Yinuo
Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Front Immunol. 2025 Aug 11;16:1643279. doi: 10.3389/fimmu.2025.1643279. eCollection 2025.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but immune-related hypersensitivity reactions remain a clinical concern. Cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, has demonstrated encouraging antitumor efficacy across various solid tumors; however, hypersensitivity or infusion-related reactions may occasionally occur.
We herein report five cases of cadonilimab-induced allergic or infusion-related reactions in patients with different advanced solid tumors. Clinical manifestations ranged from mild skin rash to severe anaphylaxis with hypotension. All patients were managed promptly with individualized anti-allergic interventions, and some were able to safely continue therapy with modified infusion protocols.
The series emphasizes the importance of early identification and tailored management of hypersensitivity reactions during cadonilimab treatment. Additionally, a comprehensive literature review was conducted summarizing current clinical trials, case reports, and real-world evidence regarding cadonilimab's efficacy and safety across multiple cancer types.
Our findings highlight both the potential risks and manageable nature of cadonilimab-induced hypersensitivity, supporting its continued clinical application with appropriate monitoring and management strategies.
免疫检查点抑制剂（ICIs）彻底改变了癌症治疗方式，但免疫相关的超敏反应仍是临床关注的问题。卡度尼利单抗是一种新型的PD-1/CTLA-4双特异性抗体，已在多种实体瘤中显示出令人鼓舞的抗肿瘤疗效；然而，超敏反应或输液相关反应偶尔仍可能发生。
我们在此报告5例不同晚期实体瘤患者发生的卡度尼利单抗引起的过敏或输液相关反应。临床表现从轻度皮疹到伴有低血压的严重过敏反应不等。所有患者均立即接受个体化抗过敏干预治疗，部分患者通过调整输液方案得以安全继续治疗。
该系列病例强调了在卡度尼利单抗治疗期间早期识别和针对性处理超敏反应的重要性。此外，还进行了全面的文献综述，总结了有关卡度尼利单抗在多种癌症类型中的疗效和安全性的当前临床试验、病例报告及真实世界证据。
我们的研究结果凸显了卡度尼利单抗引起超敏反应的潜在风险及可控性，支持通过适当的监测和管理策略继续将其用于临床。
